查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138360

全球地中海貧血治療市場-2022-2029

Global Thalassemia Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

地中海貧血治療市場的增長受到多種因素的推動，例如地中海貧血患病率的增加、全球意識的提高以及研發投資的增加。

人們對地中海貧血的認識不斷提高，預計將推動市場增長。

提高對地中海貧血的認識對於預防這種疾病非常重要。許多組織已經發起了宣傳活動，並正在為此努力。政府也通過投資這些項目來支持這項工作。例如，慶祝 5 月 8 日國際地中海貧血日是為了提高決策者和政策制定者、醫護人員、患者及其家人以及整個社區對地中海貧血的認識。大多數人對這種疾病一無所知，尤其是在亞太地區和地中海地區等流行地區。美國疾病控制和預防中心 (CDC) 正在資助一個監測血液病患者血液安全的項目。該項目被稱為“與治療性輸血相關的血紅蛋白疾病的並發症特徵”。喬治亞大學、佛羅裡達大學和加州大學舊金山分校貝尼奧夫兒童醫院奧克蘭分校正在研究血紅蛋白疾病（鐮狀細胞病、地中海貧血）患者的輸血相關並發症，並開發減少這些並發症的方法。有資金這樣做。此外，CDC 資助公共衛生實驗室協會開展篩查活動，例如實驗室需求評估，以及針對患者、護理人員和衛生保健工作者的血紅蛋白病篩查計劃。我們提供公共衛生技術支持，例如教育。

高昂的治療費用預計將阻礙全球地中海貧血治療市場的增長。

高昂的治療費用預計將阻礙全球地中海貧血治療市場的增長。

行業分析。

《全球地中海貧血治療市場報告》根據波特五力、創新、新產品發布、定價分析和管道分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

COVID-19 正在對全球地中海貧血治療市場產生重大影響。自 COVID-19 遏制協議以來，許多市場參與者的供應鏈被打亂，導致原材料短缺並擾亂供應鏈。此外，由於社會化規定，定期健康檢查很困難，大多數地中海貧血患者未被發現，對大流行期間全球地中海貧血治療市場的增長產生了負面影響。

全球地中海貧血治療市場 - 細分分析

在整個預測期內（2022-2029 年），ALPHA-地中海貧血預計將主導地中海貧血治療市場。

由於其在全球範圍內的高流行率，預計在預測期內（2022-2029 年），ALPHA地中海貧血將佔據最大的市場份額。根據美國國家罕見病組織的數據，每 1,000 名活產兒中有 4 至 20 人患有阿爾法地中海貧血症。 ALPHA地中海貧血在全世界大多數人群中都有發現，但最常見於中東、東南亞和地中海沿岸的一些國家。由於遷移增加，歐洲和北美的醫生也越來越多地遇到ALPHA-地中海貧血患者。 ALPHA地中海貧血是一種遺傳性疾病，由製造血紅蛋白所需的基因突變引起。這些突變阻止或減少血紅蛋白的產生，從而導致缺乏成熟的紅細胞和貧血。導致 ALPHA 地中海貧血的突變在亞洲、印度、中東和地中海地區很常見，並且在高達 20% 的人口中發現。然而，由於現代人類的不斷遷移，病例在其他地區變得越來越普遍。地中海南部國家已經認識到 ALPHA-地中海貧血患者的增加，並正在增加資源以充分滿足不斷增長的需求，從而導致 ALPHA-地中海貧血藥物市場的全球擴張。

全球地中海貧血治療市場報告將提供對大約 40 多個市場數據表、45 多個圖表和 200 多個頁面（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 提高認識
      • 研發進展
    • 限制因素
      • 開發成本高
      • 治療費用高
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疾病類型

  • 阿爾法地中海貧血
  • β地中海貧血

第 8 章按治療類型

  • 輸血
  • 鐵螯合療法
  • 骨髓移植
  • 基因治療
  • 手術

第 9 章給藥途徑

  • 口語
  • 注入

第 10 章，最終用戶

  • 醫院和診所
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 13 章公司簡介

  • 百時美施貴寶公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Vifor Pharma
  • Kiadis Pharma
  • Gamida Cell
  • ApoPharma
  • bluebird bio, Inc.
  • Novartis AG
  • Celgene Corporation,
  • La Jolla Pharmaceutical
  • Sangamo Biosciences
  • Acceleron Pharma.

第14章 DataM

簡介目錄
Product Code: DMPH2148

Market Overview

Thalassemia Treatment Market is expected to grow at a CAGR of 10.5% during the forecasting period (2022-2029).

Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin, the protein in red blood cells that carries oxygen. This causes a shortage of red blood cells and low oxygen levels in the bloodstream, leading to various health problems. Signs and symptoms vary but may include mild to severe anemia, paleness, fatigue, yellow discoloration of the skin, and bone problems. When there are not enough healthy red blood cells, there is also not enough oxygen delivered to all the other cells of the body, which may cause a person to feel tired, weak or short of breath. This is a condition called anemia. People with thalassemia may have mild or severe anemia. Severe anemia can damage organs and lead to death.

Market Dynamics

The thalassemia treatment market growth is driven by several factors, such as an increase in the prevalence of thalassemia, a rise in global awareness and, increasing investment in research and development.

The rising awareness about thalassemia is expected to drive market growth.

An increase in awareness about thalassemia is very important for the prevention of the disease. Many organizations are working towards this cause by initiating awareness campaigns. Governments of countries are also supporting the cause by investing in these programs. For instance, International Thalassaemia Day is celebrated on May 8 to raise awareness amongst people concerned with decision and policymaking, health care professionals, patients and their families and the community at large about thalassemia. The majority of the population is unaware of the disease, especially in more prevalent areas, such as the Asia Pacific and the Mediterranean. The Center for Disease Control and Prevention (CDC) funds one project that monitors blood safety in people with blood disorders. This project is called "Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies." Georgia State University, the University of Florida, and the University of California at San Francisco Benioff Children's Hospital Oakland have been awarded funding to look at transfusion-related complications in people with hemoglobin disorders (sickle cell disease and thalassemia) and develop approaches for reducing these complications. Besides, CDC funds the Association of Public Health Laboratories to provide public health technical assistance with screening (a test to look for a disease before it is noticeable) activities, including needs assessments for laboratories, as well as education for patients, caregivers, and healthcare workers on hemoglobinopathy screening programs.

The high cost of treatment is expected to hinder global thalassemia treatment market growth.

The high cost of treatment is expected to hamper the global thalassemia treatment market growth.

Industry analysis.

The global thalassemia treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global Thalassemia Treatment market. Since COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials to disturb the supply and demand chain. Furthermore, because of the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with thalassemia undetected, negatively impacting the global Thalassemia Treatment market growth during the pandemic.

Global Thalassemia Treatment Market - Segment Analysis

The alpha-thalassemia is expected to dominate the thalassemia treatment market throughout the forecast period (2022-2029)

Alpha thalassemia is expected to hold the largest market share over the period forecast (2022-2029) owning to a higher prevalence of the disease globally. According to National Organization for Rare Disorders, alpha thalassemia occurs in 4-20 individuals per every 1,000 births. Alpha thalassemia is found in most populations worldwide but is most common in the Middle East, Southeast Asia, and certain Mediterranean countries. Doctors in Europe and North America are also increasingly encountering patients with alpha-thalassemia due to increased migration. Alpha-thalassemia is an inherited disease caused by mutations in a gene required for making a component of hemoglobin. Those mutations either prevent or reduce the production of hemoglobin, which can cause a shortage of mature red blood cells and lead to anemia. The mutations that cause alpha-thalassemia are more common in Asia, India, the Middle East and the Mediterranean where they are found in up to 20% of the population. But the increase in modern migration means that cases are now cropping up more often in other regions. Southern Mediterranean countries recognize the rise in patients with alpha-thalassemia and have increased resources to meet the growing demand appropriately, hence increasing the market for alpha-thalassemia treatment globally.

Geographical Analysis

The North American region holds the largest market share of the global thalassemia treatment market.

North America is dominating the thalassemia treatment market in 2018 and is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase in thalassemia incidences, highly aware population, advanced healthcare infrastructure and favorable government initiatives. The cases of thalassemia disorder are increasing in the region due to migration. Thalassemia, once a rarity in the US, is increasingly encountered in clinical practice due to shifts in immigration. Thalassemia is becoming more prevalent in the US due to the immigration of people from affected regions; according to Cooley's Anemia Foundation, 12% of patients with B-thalassemia in their US patient database were adopted from other countries. Furthermore, many organizations and societies are working in this region to spread awareness about thalassemia and ensure its dominance over the global market.

Competitive Landscape

Some of the major key players in the market are Vifor Pharma, Kiadis Pharma, Gamida Cell, ApoPharma, bluebird bio, Inc., Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, La Jolla Pharmaceutical, Sangamo Biosciences, and Acceleron Pharma. In the thalassemia treatment market, bluebird bio-Inc. will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the thalassemia treatment market globally. For instance, on April 16, 2021, Sanofi acquired Kiadis. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Bristol-Myers Squibb Company

Overview:

The Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York City. BMS is a leading pharmaceutical company and has consistently ranked among the largest U.S. corporations. For fiscal 2021, it had total revenue of $46.4 billion.

Product Portfolio:

The product portfolio of Bristol-Myers Squibb Company for thalassemia treatment contains REBLOZYL.

The global thalassemia treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Awareness
      • 4.1.1.2. Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. The High Development Cost
      • 4.1.2.2. High Treatment Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Alpha Thalassemia
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Beta Thalassemia

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Blood Transfusion
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Iron Chelation Therapy
  • 8.4. Bone Marrow Transplant
  • 8.5. Gene Therapy
  • 8.6. Surgery

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of administration Segment
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Injectable

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals and Clinics
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Other

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Bristol-Myers Squibb Company
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Vifor Pharma
  • 13.3. Kiadis Pharma
  • 13.4. Gamida Cell
  • 13.5. ApoPharma
  • 13.6. bluebird bio, Inc.
  • 13.7. Novartis AG
  • 13.8. Celgene Corporation,
  • 13.9. La Jolla Pharmaceutical
  • 13.10. Sangamo Biosciences
  • 13.11. Acceleron Pharma.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us